As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too
Recent efforts in Washington to restrict U.S. investment and partnerships with Chinese biotech firms have triggered a fierce backlash from industry leaders and intensified concerns in Beijing, turning biotech into the latest front in the U.S.-China tech rivalry.
As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too
Recent efforts in Washington to restrict U.S. investment and partnerships with Chinese biotech firms have triggered a fierce backlash from industry leaders and intensified concerns in Beijing, turning biotech into the latest front in the U.S.-China tech rivalry.